Glaukos Lowers 2020 Guidance, Citing 'Competitive Headwind' In MIGS Business
Glaukos Corp. said it expects rising competition in the US microinvasive glaucoma surgery (MIGS) space in 2020 from Ivantis along with surgical procedures.
You may also be interested in...
In his recent report on Alcon, BTIG analyst Ryan Zimmerman estimated that its pharmaceutical portfolio could generate close to $900m in fiscal year 2022.
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were signed in March and April 2019.
In the randomized COMPARE trial, eyes treated with Ivantis' Hydrus Microstent were about twice as likely to not need medication than eyes treated with two Glaukos iStent trabecular micro-bypass stents one year after implant The one-year results of the trial have been accepted for publication in Opthalmology.